novabiotics.co.uk Report : Visit Site

Technical data of the novabiotics.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host novabiotics.co.uk. Currently, hosted in United Kingdom and its service provider is Freethought Internet Limited .

the related websites

converged.co.uk luminaderm.com townsendinvestments.com ktpws.org.uk onorach.com edenscott.com scottishlifesciencesassociation.org.uk peptideconferences.org lingscars.com moooi.com lotuscars.com itsnicethat.com telegraph.co.uk keynote.com profactum.com voa.com arup.com etruriadesign.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called LiteSpeed containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

novabiotics news and events about us board and management investors corporate social responsibility therapeutic focus technology pipeline novexatin np213 lynovex nm001 nylexa nm002 novamycin np339 novarifyn np432 luminaderm np108 contact us thanks taking nature’s lead in antimicrobials novabiotics ceo named as one of the top 30 woman leaders in uk healthcare 14-jun-2018 cysteamine, an endogenous aminothiol, and cystamine, the disulfide product of oxidation, increase pseudomonas aeruginosa sensitivity to reactive oxygen and nitrogen species and potentiate therapeutic antibiotics against bacterial infection. 03-apr-2018 how lynovex works to boost antibiotics in combatting pseudomonas aeruginosa infection in cystic fibrosis 19-mar-2018 novabiotics’ lynovex receives fast track designation for cystic fibrosis exacerbations 12-mar-2018 novabiotics chief executive officer elected as a fellow of the royal society of edinburgh 27-feb-2018 novabiotics and biopharma dealmakers’ ‘fighting infectious diseases’ webcast 22-feb-2018 novabiotics receives most innovative eu biotech sme 2017 award 23-nov-2017 enrolment reaches 50% in lynovex care-cf-1 trial 02-nov-2017 novabiotics at north american cystic fibrosis conference (nacfc), indianapolis 30-oct-2017 reflections from world amr congress 19-oct-2017 europabio announces the finalists for the most innovative european biotech sme awards 2017 18-oct-2017 novabiotics at world antimicrobial resistance congress, washington 13-sep-2017 novabiotics at asm/escmid conference 31-aug-2017 novabiotics at the 7th international meeting on antimicrobial peptides 21-aug-2017 novabiotics chief executive responds to public health england warning on candida auris fungus 16-aug-2017 novabiotics featured on stv news 04-aug-2017 new drug kills mrsa – including strains with antibiotic resistance 03-aug-2017 50th patient recruited for care- cf-1 lynovex clinical study 01-aug-2017 novabiotics’ novel antimicrobial luminaderm highly effective against multi drug resistant mrsa 16-jun-2017 novabiotics participating in bio 2017 in san diego 15-jun-2017 novabiotics at european cystic fibrosis conference in seville 06-jun-2017 novabiotics at american society for microbiology 26-may-2017 30 subjects now randomised in lynovex care-cf-1 trial 10-may-2017 novabiotics contribution to eccmid 2017 13-apr-2017 novabiotics quality management system achieves iso 9001 certification 11-apr-2017 novabiotics to host live twitter lynovex q&a 24-mar-2017 novabiotics chief executive addresses 'superbugs & superdrugs' conference on antimicrobial drug discovery 21-mar-2017 novabiotics ceo to speak at 19th superbugs & superdrugs conference 17-mar-2017 novabiotics secures an additional £3.0 million investment from woodford investment management 03-mar-2017 novabiotics ceo to speak at 10th berlin conference on life sciences 21-feb-2017 novabiotics at eccmid 2017 25-jan-2017 novabiotics ceo featured as one of 15 women leading in european biotech 18-jan-2017 novabiotics announces first patients dosed in lynovex clinical study 16-jan-2017 commercial collaboration deal for (oral) lynovex® 05-aug-2016 novabiotics "one to watch" for 2017 14-jul-2016 novabiotics announces new data on cysteamine (nylexa™) as an antimicrobial resistance breaker in multi drug resistant bacteria 18-jun-2016 novabiotics highlights importance of co-ordinated approach to antimicrobial resistance 07-jun-2016 novabiotics discusses innovation for antimicrobial resistance at bio 03-jun-2016 lynovex clinical trial data published 12-may-2016 novabiotics wins investment of the year 05-feb-2016 sad news on novabiotics' co-founder and first chairman 10-sep-2015 lynovex® activity in cf sputum & against the emerging cf pathogen, mycobacterium abscessus 12-aug-2015 positive lynovex phase iia data presented at the 38th european cystic fibrosis symposium 12-jun-2015 novabiotics raises £5.0 million in a private placement from woodford investment management 19-jan-2015 dr deborah o’neil named ey uk health products & services entrepreneur of 2014 07-oct-2014 novabiotics receives orphan drug status from fda 16-sep-2014 initiation of a phase iia clinical study for lynovex® in cystic fibrosis 25-jun-2014 novabiotics’ dr deborah o’neil named as an ey scotland entrepreneur of 2014 20-jun-2014 collaboration between novabiotics and the cystic fibrosis trust 31-jan-2014 novabiotics’ lynovex® gains support from the uk’s cystic fibrosis trust 30-oct-2013 novabiotics enters into agreement with taro 24-aug-2013 excellent results from the unblinding of the novexatin® phase iia clinical trial 08-jul-2010 newer older novabiotics ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. the company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (cf), novexatin, a potential step change therapy for onychomycosis (being co-developed with and out-licensed to taro pharmaceuticals) and novamycin, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. novexatin and novamycin are among the first in class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform. lynovex and nylexa have been developed as novel antimicrobial adjunct therapies from the company's more recently established aminothiol platform. novabiotics ltd cruickshank building, craibstone, aberdeen, ab21 9tr, uk tel: +44 (0)1224 711377 registered company no. sc272344 novabiotics inc 9121 anson way, suite 200, raleigh, north carolina 27615, us tel: +1 919 578 4216 fax: +1 919 573 9409 news and events about us therapeutic focus technology pipeline contact us

URL analysis for novabiotics.co.uk

http://www.novabiotics.co.uk/news/novabiotics-discusses-innovation-for-antimicrobial-resistance-at-bio
http://www.novabiotics.co.uk/news/novabiotics-chief-executive-addresses-superbugs-superdrugs-conference-on-antimicrobial-drug-discovery
http://www.novabiotics.co.uk/news/novabiotics-receives-orphan-drug-status-from-fda
http://www.novabiotics.co.uk/news/novabiotics-wins-investment-of-the-year
http://www.novabiotics.co.uk/about-us
http://www.novabiotics.co.uk/news/50th-patient-recruited-for-care-cf-1-lynovex-clinical-study
http://www.novabiotics.co.uk/news/60-subjects-now-randomised-in-lynovex-care-cf-1-trial
http://www.novabiotics.co.uk/news/initiation-of-a-phase-iia-clinical-study-for-lynovex-in-cystic-fibrosis
http://www.novabiotics.co.uk/pipeline/novarifyn-np432
http://www.novabiotics.co.uk/news/novabiotics-chief-executive-responds-to-public-health-england-warning-on-candida-auris-fungus
http://www.novabiotics.co.uk/news/novabiotics-at-north-american-cystic-fibrosis-conference-nacfc-indianapolis
http://www.novabiotics.co.uk/news/lynovex-activity-in-cf-sputum-against-the-emerging-cf-pathogen-mycobacterium-abscessus
http://www.novabiotics.co.uk/pipeline/lynovex-nm001
http://www.novabiotics.co.uk/news/novabiotics-dr-deborah-oneil-named-as-an-ey-scotland-entrepreneur-of-2014
http://www.novabiotics.co.uk/news/novabiotics-participating-in-bio-2017-in-san-diego

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "novabiotics.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 176 seconds

WHOIS lookup made at 17:29:31 23-Jul-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS novabiotics.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME novabiotics.co.uk

NSERVER

  NS2.CONVERGED.CO.UK 195.72.131.169

  NS0.CONVERGED.CO.UK 89.104.224.1

  NS1.CONVERGED.CO.UK 89.104.232.1

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .